EyePoint Pharmaceuticals

EyePoint Pharmaceuticals

Biotechnology Research

Watertown, MA 12,081 followers

Delivering Innovation to the Eye™ NOW HIRING!

About us

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Watertown, MA
Type
Public Company
Specialties
Ophthalmology, Glaucoma, WetAMD, Optometry, Eye Disease, and Retinal Disease

Locations

Employees at EyePoint Pharmaceuticals

Updates

Affiliated pages

Similar pages

Browse jobs

Funding

EyePoint Pharmaceuticals 10 total rounds

Last Round

Post IPO equity

US$ 215.9M

See more info on crunchbase